CoChat
Sign Up
Cited by 20Pharmacology and Obesity TreatmentPulmonary Hypertension Research and TreatmentsCardiovascular Function and Risk Factors

Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

Guven, A., Koksal, N., Cetinkaya, A., Sokmen, G., Ozdemir, R.·2004·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2004.00314.x
Open this paper in CoChat — free account

Abstract

Aim: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti‐obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine. Methods: One hundred and six obese patients (51 men and 55 women) determined to have minimal tricuspid regurgitation (TR) on echocardiographic examination were included in the study. All patients had a complete physical examination, complete blood count and measurement of lipid parameters, and echocardiography was performed by which cardiac valves and PAP were evaluated. After the mean duration of 24‐week of follow up, all examinations were repeated for each patient. Results: The drug was well tolerated by all patients for the follow‐up period. A significant weight loss was recorded in all patients compared to the baseline values (93.1 ± 9.6 kg vs. 85.8 ± 7.7 kg, p < 0.001). Blood pressures and heart rate of the patients increased compared to the baseline measurements (systolic 122.3 ± 8.5 vs. 124 ± 10.2 mmHg, p = 0.128, diastolic 79.3 ± 4.7 vs. 80 ± 5.7 mmHg, p = 0.42 and heart rate 79.5 ± 6.5 vs. 85 ± 5.7 beats/min, p < 0.001). Echocardiographically determined aortic or mitral valve dysfunction appeared in none of the patients. PAP lightly increased after the treatment but the difference between pre and post‐treatment values was not found statistically significant (14.7 ± 1.8 vs. 16.3 ± 1.6 mmHg, p = 0.06). Conclusions: A 24‐week treatment with sibutramine does not affect heart valves and pulmonary artery pressure.

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00314.x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neither orlistat nor sibutramine has significant effects on cardiac dimensions, valvular function, or pulmonary artery pressures when given for up to 6 mo.

    “Neither drug has significant effects on cardiac dimensions, valvular function, or pulmonary artery pressures when given for up to 6 mo (125, 393).”

    From Cardiac remodeling in obesity (2008) · cites this paper as [125]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Guven, A., Koksal, N., Cetinkaya, A., Sokmen, G., & Ozdemir, R.
Affiliations
Kahramanmaraş Sütçü İmam University (TR)
ORCID
Sokmen, G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2003-12-15
Volume
6
Issue
1
Pages
50-55
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2004.00314.x
OpenAlex
W1992269252
Cited by
20
References
25
Citations by year
2025: 1 · 2023: 1 · 2021: 1 · 2013: 1 · 2012: 1
FWCI
0.86
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
sibutramine, obesity, pulmonary artery pressure, tricuspid regurgitation, valvular heart disease, anti-obesity drugs, weight loss, blood pressure, heart rate, drug safety
MeSH terms
Adult, Appetite Depressants, Blood Pressure, Cyclobutanes, Echocardiography, Female, Follow-Up Studies, Heart Rate, Humans, Lipids, Male, Middle Aged, Obesity, Pulmonary Artery, Risk Factors, Tricuspid Valve Insufficiency, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review